Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study
Yao, J Fazio, N Singh, S Buzzoni, R Carnaghi, C Wolin, E Tomasek, J Raderer, M Lahner, H Voi, M
Yao, J
Fazio, N
Singh, S
Buzzoni, R
Carnaghi, C
Wolin, E
Tomasek, J
Raderer, M
Lahner, H
Voi, M
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2015
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study. 2015, 51 S709-S710 Eur J Cancer